Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr-Jun;12(2):67-68.
doi: 10.4103/2045-9912.326003.

Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report

Fatih Uzer  1 , Aykut Cilli  1
Affiliations
Case Reports

Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac®): a case report

Fatih Uzer et al. Med Gas Res. 2022 Apr-Jun.

Abstract

A 76-year-old female received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac, Sinovac®, Beijing, China) and subsequently experienced chest discomfort. A computed tomography performed 1 day after vaccination showed multiple infiltrations in both lungs and ground-glass shadows in both lung fields. Her fingertip oxygen saturation was 81% and there was widespread wheezing on physical examination. Based on these findings, the patient was hospitalized with a preliminary diagnosis of drug-induced pneumonitis and acute asthma exacerbation due to a SARS-CoV-2 vaccine. During her hospitalization, 40 mg/d systemic steroid, 4 times a day salbutamol nebulized, 2 L/min inhaled oxygen therapy and 400 mg/d moxifloxacin intravenous were administered for 5 days. One month later, the thorax computed tomography scan revealed that the previous findings were almost completely regressed.

Keywords: SARS-CoV-2; adverse event; allergy; computed tomography; infiltrations; side effect; systemic inflammation; vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

No.

Figures

Figure 1
Figure 1
Chest X-ray of the patient: infiltration at bilateral low zones. Note: Arrows indicate infiltration. R: Right.
Figure 2
Figure 2
Thorax CT of the patient immediately after the vaccination. Note: CT shows peribronchial thickening and ground-glass shadows. Arrows indicate ground-glass shadow. CT: Computed tomography.
Figure 3
Figure 3
Thorax CT of the patient after 1 month. Note: CT shows signs of small airway diseases, there is no ground-glass shadows. CT: Computed tomography.
See this image and copyright information in PMC

References

    1. Palacios R, Patiño EG, de Oliveira Piorelli R, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853. - PMC - PubMed
    1. World Health Organization. The Sinovac COVID-19 vaccine: What you need to know. [Accessed by July 27, 2021]. https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid- ....
    1. Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222. - PMC - PubMed
    1. Baraniuk C. What do we know about China’s covid-19 vaccines. BMJ? 2021;373:n912. - PubMed
    1. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192. - PMC - PubMed

Publication types